

Elizabeth S Klings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9517287/publications.pdf>

Version: 2024-02-01

79
papers

2,642
citations

230014

27
h-index

214428

50
g-index

79
all docs

79
docs citations

79
times ranked

3368
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. <i>Expert Review of Hematology</i> , 2022, 15, 117-125.	1.0	7
2	Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease. <i>Thrombosis Update</i> , 2022, 6, 100101.	0.4	5
3	High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells. <i>ACS Omega</i> , 2022, 7, 14009-14016.	1.6	3
4	Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	3
5	Common Complications of Sickle Cell Disease: A Simulation-Based Curriculum. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 2021, 17, 11139.	0.5	0
6	Critical Care of Patients With Cardiopulmonary Complications of Sarcoidosis. <i>Journal of Intensive Care Medicine</i> , 2021, , 088506662199304.	1.3	1
7	Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	7
8	Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. <i>European Journal of Haematology</i> , 2021, 107, 54-62.	1.1	5
9	Development and Validation of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data. <i>Chest</i> , 2021, 159, 1986-1994.	0.4	10
10	Long-term Exercise After Pulmonary Rehabilitation (LEAP): a pilot randomised controlled trial of Tai Chi in COPD. <i>ERJ Open Research</i> , 2021, 7, 00025-2021.	1.1	7
11	Exploring Tai Chi Exercise and Mind-Body Breathing in Patients with COPD in a Randomized Controlled Feasibility Trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 288-298.	0.7	5
12	Evaluation of leukopenia during sepsis as a marker of sepsis-defining organ dysfunction. <i>PLoS ONE</i> , 2021, 16, e0252206.	1.1	25
13	The Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-related Pulmonary Hypertension. <i>Arthritis Care and Research</i> , 2021, , .	1.5	5
14	Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. <i>Blood Advances</i> , 2021, 5, 207-215.	2.5	59
15	Reply: Ethnically Diverse Normative Data for Diffusing Capacity and Lung Volumes. <i>Annals of the American Thoracic Society</i> , 2020, 17, 129-130.	1.5	0
16	<p>Development of a Severity Classification System for Sickle Cell Disease</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 625-633.	0.7	12
17	BEAM study (Breathing, Education, Awareness, Movement): a randomised controlled feasibility trial of tai chi exercise in patients with COPD. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000697.	1.2	19
18	Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-analysis. <i>Lung</i> , 2020, 198, 535-545.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005993.	0.9	7
20	The effect of anticoagulant choice on venous thromboembolism recurrence and bleeding in sickle cell disease. <i>American Journal of Hematology</i> , 2020, 95, E279.	2.0	5
21	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. <i>Respiratory Medicine</i> , 2020, , 123-134.	0.1	1
22	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2019, 16, e17-e32.	1.5	33
23	Response. <i>Chest</i> , 2019, 155, 1077-1078.	0.4	0
24	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. <i>Blood Advances</i> , 2019, 3, 4002-4020.	2.5	21
25	Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data. <i>Chest</i> , 2019, 155, 680-688.	0.4	29
26	A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells. <i>Molecular Pharmaceutics</i> , 2018, 15, 1954-1963.	2.3	18
27	Commentary: Heterogeneity of respiratory disease in children and young adults with sickle cell disease. <i>Thorax</i> , 2018, 73, 503-503.	2.7	1
28	Prostacyclin-analog therapy in sickle cell pulmonary hypertension. <i>Haematologica</i> , 2017, 102, e163-e165.	1.7	15
29	Clinical and laboratory findings associated with sleep disordered breathing in sickle cell disease. <i>American Journal of Hematology</i> , 2017, 92, E649-E651.	2.0	13
30	Standard measures for sickle cell disease research: the PhenX Toolkit sickle cell disease collections. <i>Blood Advances</i> , 2017, 1, 2703-2711.	2.5	22
31	Chronic Pulmonary Complications of Sickle Cell Disease. <i>Chest</i> , 2016, 149, 1313-1324.	0.4	43
32	Development of a Triazolylsulfide Compound That Increases the Affinity of Hemoglobin for Oxygen and Reduces Hypoxic Sickling of Sickle Cells. <i>Blood</i> , 2016, 128, 3642-3642.	0.6	1
33	Sickle cell disease: wheeze or asthma?. <i>Asthma Research and Practice</i> , 2015, 1, 14.	1.2	14
34	Long-term Exercise After Pulmonary Rehabilitation (LEAP): Design and rationale of a randomized controlled trial of Tai Chi. <i>Contemporary Clinical Trials</i> , 2015, 45, 458-467.	0.8	29
35	Management of Patients With Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 91.	3.8	4
36	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. <i>British Journal of Haematology</i> , 2015, 169, 887-898.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Pulmonary hypertension in sickle cell disease: diagnosis and management. Hematology American Society of Hematology Education Program, 2014, 2014, 425-431.	0.9	11
38	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197
39	Response to "Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.. Haematologica, 2014, 99, e19-e19.	1.7	1
40	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	1.7	40
41	Making It Personal: Using Genomics to Predict Pulmonary Hypertension in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 304-305.	2.5	1
42	A Genome-Wide Association Study of Total Bilirubin and Cholelithiasis Risk in Sickle Cell Anemia. PLoS ONE, 2012, 7, e34741.	1.1	55
43	Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF- κ B signaling pathway. Molecular Immunology, 2012, 50, 117-123.	1.0	26
44	Keeping it in the family: Three relatives with HbSC disease and simultaneous acute pulmonary emboli. American Journal of Hematology, 2012, 87, 101-104.	2.0	3
45	Ancestry of African Americans with sickle cell disease. Blood Cells, Molecules, and Diseases, 2011, 47, 41-45.	0.6	35
46	Severe sickle cell anemia is associated with increased plasma levels of TNF α and VCAM-1. American Journal of Hematology, 2011, 86, 220-223.	2.0	34
47	Hemolytic-Anemia-Associated Pulmonary Hypertension: Sickle-Cell-Disease- and Thalassemia-Associated Pulmonary Hypertension. , 2011, , 1269-1282.		0
48	Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. American Journal of Hematology, 2010, 85, 29-35.	2.0	83
49	Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5 α olfactory receptor gene cluster. Blood, 2010, 115, 1815-1822.	0.6	146
50	Sickle cell anemia and vascular dysfunction: The nitric oxide connection. Journal of Cellular Physiology, 2010, 224, 620-625.	2.0	84
51	Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: Differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine, 2009, 46, 72-78.	1.4	9
52	Hyperoxia-Induced Lung Injury in Gamma-Glutamyl Transferase Deficiency Is Associated with Alterations in Nitrosative and Nitritative Stress. American Journal of Pathology, 2009, 175, 2309-2318.	1.9	12
53	Pulmonary hypertension of sickle cell disease: More than just another lung disease. American Journal of Hematology, 2008, 83, 4-5.	2.0	32
54	Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: Clinical characteristics and association with soluble adhesion molecule expression. American Journal of Hematology, 2008, 83, 547-553.	2.0	58

#	ARTICLE	IF	CITATIONS
55	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. <i>Blood</i> , 2008, 111, 402-410.	0.6	157
56	Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 2195-2203.	0.7	28
57	A Transgenic Mouse Model for Adult Acute Chest Syndrome.. <i>Blood</i> , 2007, 110, 2259-2259.	0.6	12
58	Low Erythrocyte Glutamine-to-Glutamate Ratio: A Novel Biomarker of Hemolysis and Pulmonary Hypertension in Sickle Cell Disease.. <i>Blood</i> , 2007, 110, 2257-2257.	0.6	0
59	Predicting Acute Chest Syndrome in Sickle Cell Disease Patients Hospitalized for Acute Vasoocclusive Events.. <i>Blood</i> , 2007, 110, 3390-3390.	0.6	2
60	Present and Future Treatment Strategies for Pulmonary Arterial Hypertension. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 271-282.	1.4	8
61	Abnormal Pulmonary Function in Adults with Sickle Cell Anemia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1264-1269.	2.5	177
62	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. <i>Blood</i> , 2006, 108, 1208-1208.	0.6	7
63	Identification of Oxidative Post-Translational Modifications on Plasma Albumin in Patients with Pulmonary Hypertension of Sickle Cell Anemia.. <i>Blood</i> , 2006, 108, 1215-1215.	0.6	0
64	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. <i>Blood</i> , 2006, 108, 788-788.	0.6	1
65	Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. <i>American Journal of Hematology</i> , 2005, 78, 240-242.	2.0	41
66	Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. <i>Physiological Genomics</i> , 2005, 21, 293-298.	1.0	19
67	Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2004, 350, 2521-2522.	13.9	19
68	A Sickle Transgenic Mouse Model of Acute Chest Syndrome.. <i>Blood</i> , 2004, 104, 3585-3585.	0.6	0
69	The Pathogenesis of HIV-Associated Pulmonary Hypertension. , 2003, 40, 71-82.		14
70	Î³-Glutamyl transferase deficiency results in lung oxidant stress in normoxia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 283, L766-L776.	1.3	63
71	Cellular glutathione peroxidase deficiency and endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H1255-H1261.	1.5	166
72	Current Management of Primary Pulmonary Hypertension. <i>Drugs</i> , 2001, 61, 1945-1956.	4.9	31

#	ARTICLE	IF	CITATIONS
73	Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. <i>Respiratory Research</i> , 2001, 2, 280.	1.4	103
74	Lipopolysaccharide Binding Protein Potentiates Airway Reactivity in a Murine Model of Allergic Asthma. <i>Journal of Immunology</i> , 2001, 166, 2063-2070.	0.4	31
75	IV Epoprostenol for Systemic Sclerosis. <i>Chest</i> , 2000, 118, 881-882.	0.4	1
76	Epoprostenol for Pulmonary Hypertension in Scleroderma. <i>Annals of Internal Medicine</i> , 2000, 133, 158.	2.0	3
77	Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. <i>Journal of Clinical Investigation</i> , 2000, 106, 483-491.	3.9	353
78	Endothelial cell nitric oxide production in acute chest syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 277, H1579-H1592.	1.5	28
79	Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin). <i>Arthritis and Rheumatism</i> , 1999, 42, 2638-2645.	6.7	81